IAP antagonists

Patent metadata

Field	Value
Publication number	US-9345740-B2
Application number	US-201314413791-A
Country	US
Kind code	B2
Filing date	Jul 10, 2013
Priority date	Jul 10, 2012
Publication date	May 24, 2016
Grant date	May 24, 2016

Abstract

There are disclosed compounds that modulate the activity of inhibitors of apoptosis (IAPs), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders and disorders of dysregulated apoptosis, such as cancer, utilizing the compounds of the invention.

First claim

What is claimed is:

1. A compound of Formula (I)

wherein:
X is —(CR 16 R 17 ) m ,

or X is absent;
Y and Z are independently —O—, C═O, NR 6 or are absent;
R 1 is optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted alkylaryl or optionally substituted aryl;
R 2 and R 3 are independently optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted arylalkyl or optionally substituted aryl;
R 4 and R 5 are independently optionally substituted alkyl or optionally substituted cycloalkyl;
R 6 is hydrogen or (C 1 -C 3 )alkyl;
R 7 and R 8 are independently hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl;
R 9 and R 10 are independently hydrogen, optionally substituted alkyl, or R 9 and R 10 may be taken together to form a ring;
R 11 to R 14 are independently hydrogen, halogen, optionally substituted alkyl or OR 15 ;
R 15 is hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl;
R 16 and R 17 are independently hydrogen, halogen or optionally substituted alkyl;
R 50 and R 51 are independently optionally substituted alkyl, or R 50 and R 51 are taken together to form a ring;
m and n are independently an integer from 0-4;
o and p are independently an integer from 0-3;
q is an integer from 0-4; and
r is an integer from 0-1;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

2. The compound according to claim 1 wherein:
X is

or X is absent;
R 1 is optionally substituted alkyl or optionally substituted alkylaryl;
R 2 and R 3 are independently optionally substituted alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl or optionally substituted arylalkyl;
R 4 and R 5 are independently optionally substituted alkyl;
R 6 is hydrogen or methyl;
R 7 and R 8 are independently hydrogen, optionally substituted alkyl or optionally substituted cycloalkyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

3. The compound according to claim 2 wherein:
R 1 is (C 1 -C 6 )alkyl;
R 2 and R 3 are independently alkyl, cycloalkyl, cycloalkylalkyl or phenylalkyl, wherein the phenyl group is substituted with one or more alkyl or halogen groups;
R 4 and R 5 are independently (C 1 -C 3 )alkyl;
R 7 and R 8 are independently (C 1 -C 3 )alkyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

4. The compound according to claim 3 wherein:
R 1 is t-butyl;
R 2 is 1,2,3,4-tetrahydronaphthalenyl;
R 3 is alkyl, cycloalkyl, cycloalkylalkyl or phenylalkyl, wherein the phenyl group is substituted with one or more fluoro groups;
R 4 and R 5 are independently methyl or ethyl;
R 7 and R 8 are independently methyl or ethyl;
R 6 is hydrogen;
R 50 and R 51 are independently methyl, ethyl or propyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

5. A compound of Formula (II)

wherein:
X is —(CR 16 R 17 ) m ,

or X is absent;
Y and Z are independently —O—, C═O, NR 6 or are absent;
R 4 is optionally substituted alkyl or optionally substituted cycloalkyl;
R 6 is hydrogen or (C 1 -C 3 )alkyl;
R 50 and R 51 are independently methyl, ethyl or propyl;
or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof.

6. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

7. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable carrier.

Assignees

• Bristol Myers Squibb Co

Inventors

• Kim Kyoung S

Classifications

• C07F7/0812 Primary

  comprising a heterocyclic ring · CPC title

• A61K38/06 Primary

  Tripeptides · CPC title

• C07K5/0806

  the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title